In HFD-induced obese mice, the level of leptin increased, and the level of adiponectin decreased; the administration of YC-1102 decreased leptin levels and increased adiponectin levels in a dose-dependent manner, implying an ameliorating effect of YC-1102 on obesity and its related symptoms. Here, LEP is linked to obesity disorder.